Zentalis Pharmaceuticals (ZNTL) Projected to Release Quarterly Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is expected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $4.62 on Wednesday. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95. The firm has a market capitalization of $328.90 million, a P/E ratio of -2.67 and a beta of 1.92. The company’s 50-day moving average is $4.19 and its 200 day moving average is $3.52.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Millennium Management LLC lifted its stake in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. grew its holdings in Zentalis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after purchasing an additional 19,768 shares during the period. Renaissance Technologies LLC increased its position in Zentalis Pharmaceuticals by 24.0% in the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock worth $3,893,000 after buying an additional 558,390 shares during the last quarter. Bank of America Corp DE increased its position in Zentalis Pharmaceuticals by 117.1% in the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after buying an additional 835,466 shares during the last quarter. Finally, Opaleye Management Inc. raised its stake in shares of Zentalis Pharmaceuticals by 342.6% in the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock valued at $1,891,000 after buying an additional 1,084,356 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Guggenheim boosted their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Finally, Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price for the company. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $6.75.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.